The incidence of kidney cancer is located in the third place of urological tumors. Worldwide, approximately more than 400,000 people are newly diagnosed with kidney cancer each year, and more than 175,000 people die from kidney cancer, with an increasing trend year by year [1]. Approximately 25-30% of the initially diagnosed patient population is diagnosed with locally progressive or metastatic renal cancer. Meanwhile, about 1/3 of patients who have received treatment still develop metastasis in the medium and long-term follow-up [2, 3]. Q: Why is this clinic specifically opened? A: The kidney cancer surgery volume of Renji Urology Department has been ranked among the top among major tertiary hospitals in Shanghai, and there are a large number of patients from all over the country visiting the clinic every year. Among them, there are many patients who are diagnosed with metastatic kidney cancer at the first visit, or some patients who have local recurrence or distant organ metastasis after receiving surgical treatment for several years. The systemic treatment for this group of patients is an urgent need to be addressed. Q: What is the current treatment for patients with metastatic kidney cancer? A: A recent clinical study (CARMENA) showed [4] that there was no overall survival disadvantage for those who took oral sunitinib targeting agents after surgical resection of kidney cancer (surgery + dosing) compared to those who took only oral sunitinib targeting agents without surgical resection of kidney cancer (dosing). The results of this study imply that drug-taking may become the dominant trend in the future among patients with metastatic kidney cancer evaluated as moderate-to-high risk. However, the vast majority of current targeted drug therapy for patients with metastatic kidney cancer is based on first- or second-line targeted drugs recommended by urological guidelines in the United States or Europe or empirical treatment by the primary care physician (there are 8-9 targeted drugs for kidney cancer). Based on our treatment experience, not every patient is effective with first-line or empirical drugs, which will inevitably cause delay in treatment timing and waste of time/financial cost for patients. Q: What are the special features of this specialized clinic? A: The purpose of opening the personalized treatment clinic for metastatic kidney cancer is to serve this group of people and to respond to the national service concept of “precision treatment”. First of all, we will conduct individualized screening tests for patients before using targeted drugs to clarify what kind of targeted drugs are effective for them, so as to prescribe the right drugs. Secondly, when drug resistance occurs after a period of use, we will recruit eligible patients into our upcoming clinical trials to give further targeted treatment. Again, we have established an experienced multidisciplinary discussion team that will take aggressive treatment measures for some patients with adverse reactions after systemic therapy. The purpose of our metastatic kidney cancer personalized treatment clinic is to provide personalized treatment services for each patient to prolong their lives and improve their quality of life.